RWA Wealth Partners LLC Has $700,000 Position in Penumbra, Inc. (NYSE:PEN)

RWA Wealth Partners LLC lessened its holdings in Penumbra, Inc. (NYSE:PEN) by 22.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,948 shares of the company’s stock after selling 877 shares during the period. RWA Wealth Partners LLC’s holdings in Penumbra were worth $700,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cerity Partners LLC raised its holdings in shares of Penumbra by 19.2% in the 3rd quarter. Cerity Partners LLC now owns 3,612 shares of the company’s stock worth $702,000 after buying an additional 583 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Penumbra by 15.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,225 shares of the company’s stock worth $1,404,000 after purchasing an additional 953 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Penumbra by 1.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 97,571 shares of the company’s stock worth $18,959,000 after acquiring an additional 995 shares during the last quarter. Edgestream Partners L.P. bought a new stake in shares of Penumbra during the third quarter valued at approximately $773,000. Finally, True Wealth Design LLC acquired a new stake in shares of Penumbra in the 3rd quarter valued at $26,000. Institutional investors own 88.88% of the company’s stock.

Penumbra Stock Up 1.4 %

Shares of Penumbra stock opened at $271.19 on Wednesday. Penumbra, Inc. has a 52-week low of $148.00 and a 52-week high of $310.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. The business’s 50 day simple moving average is $274.68 and its 200 day simple moving average is $244.25. The firm has a market cap of $10.45 billion, a PE ratio of 797.62, a P/E/G ratio of 2.83 and a beta of 0.51.

Penumbra (NYSE:PEN) last announced its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.09. The business had revenue of $315.52 million for the quarter, compared to analyst estimates of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. On average, analysts predict that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on PEN. Robert W. Baird lifted their price target on shares of Penumbra from $305.00 to $328.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 19th. Needham & Company LLC reaffirmed a “hold” rating on shares of Penumbra in a research note on Wednesday, February 19th. Morgan Stanley lifted their price objective on shares of Penumbra from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 19th. Royal Bank of Canada increased their target price on shares of Penumbra from $285.00 to $313.00 and gave the stock an “outperform” rating in a report on Wednesday, February 19th. Finally, Wells Fargo & Company upped their price objective on shares of Penumbra from $275.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $294.47.

Insider Transactions at Penumbra

In other news, Director Arani Bose sold 12,000 shares of the stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $283.77, for a total value of $3,405,240.00. Following the completion of the sale, the director now owns 314,819 shares of the company’s stock, valued at approximately $89,336,187.63. This represents a 3.67 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Johanna Roberts sold 600 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $287.43, for a total transaction of $172,458.00. Following the sale, the executive vice president now directly owns 66,539 shares in the company, valued at $19,125,304.77. This trade represents a 0.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 93,518 shares of company stock worth $26,400,219 in the last three months. Insiders own 5.00% of the company’s stock.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.